Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.50 |
| ▸ | ITGAV | P06756 | 3/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 8/20 | 0.48 |
| ▸ | MC5R | P33032 | 8/20 | 0.48 |
| ▸ | MC3R | P41968 | 8/20 | 0.48 |
| ▸ | MC1R | Q01726 | 8/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.48 |
| ▸ | TSLP | Q969D9 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30121037 | 1.00 | ITGB3 (0.50) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL30121057 | 1.00 | ITGB3 (0.50) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL24975089 | 0.94 | ITGB3 (0.54) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL31668453 | 0.93 | CXCR4 (0.58) | CXCR4 | |
| SCHEMBL31668480 | 0.93 | CXCR4 (0.58) | CXCR4 | |
| SCHEMBL8207851 | 0.91 | MC4R (0.48) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL27423920 | 0.91 | MC4R (0.48) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL22872704 | 0.91 | ITGB3 (0.59) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL20888358 | 0.91 | ITGB3 (0.58) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL21766911 | 0.91 | ITGB3 (0.58) | ITGB3ITGAVITGB5ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243244-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| EP-4314016-A1 | CYCLIC CELL PENETRATING PEPTIDES | Entrada Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022213118-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243244-A1 | CYCLIC CELL PENETRATING PEPTIDES | SLC47A1, SLC47A2, VIP | ITGB3 3430/4885ITGAV 2250/4885ITGB5 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.